De-Identified and Anonymized Data: Understanding the Difference and How They Drive Clinical Trials

The pandemic has been hard on healthcare. Shifting to remote work introduced a host of new challenges for IT teams, while evolving restrictions meant a backlog in critical patient procedures. This new normal has also impacted clinical trials. As noted by Center Watch, while more than 5,500 trials were planned in 2021 — 14 percent more than in 2020 and 19 percent more than in 2019 — the sheer number of these trials combined with ongoing staff shortages has created a logjam in trial efforts.
De-identified and anonymized data offer a way for healthcare organizations to expedite clinical trial…